Nasal spy mission: can FluMist's inner workings reveal a better flu vaccine?
NCT ID NCT07726862
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This study investigates how the immune system inside the nose responds to the FluMist nasal flu vaccine in healthy adults aged 18 to 65. Participants receive a single dose of the vaccine, and researchers collect nasal swabs and gentle saline washes before vaccination and again two and four days later. By analyzing these samples for changes in immune cells, proteins, and viral activity, the study aims to uncover how flu vaccines work at the very site where infection starts—potentially guiding the development of more effective vaccines in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- FluMist (Live Attenuated Influenza Vaccine) given as a nasal spray
- What this could lead to
- If successful, this research could help scientists design better flu vaccines that work at the site where infection begins.
- What could go wrong
- This is a very small, early-stage study with only 20 participants, so findings may not apply broadly. There is no direct benefit expected for volunteers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy adults aged 18 to 65 years * Non-smokers (no smoking or vaping within the past 6 months) * No chronic lung disease or significant chronic medical conditions * No current or recent (within 1 month) upper or lower respiratory infection * Able and willing to provide informed consent * Have not received the current seasonal influenza vaccine * Able to comply with study procedures and follow-up visits Exclusion Criteria: * Age under 18 or over 65 years * Pregnancy or breastfeeding * Prisoners * Non-English speaking individuals * Immunocompromised individuals (including HIV/AIDS, immunosuppressive therapy, chemotherapy, or primary immunodeficiency) * Chronic medical conditions including asthma, chronic lung, liver, kidney, neurologic, hematologic, metabolic, or significant cardiovascular disease (except isolated hypertension) * History of chronic sinusitis or significant nasal allergies requiring frequent or daily treatment * Acute moderate or severe illness at time of enrollment, with or without fever * Receipt of influenza vaccine during the current season or within the past 2 weeks * Receipt of another live vaccine within 4 weeks prior to enrollment or planned during study period * Use of influenza antiviral medications (e.g., oseltamivir, zanamivir) within 48 hours prior to vaccination or planned use within 14 days after vaccination * History of severe allergic reaction to influenza vaccine or any component of FluMist (including egg allergy if applicable) * History of Guillain-Barré syndrome following influenza vaccination * Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mucosal immune response to influenza vaccination are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States